Amgen Inc. (BCBA:AMGN)

Market Cap	225.43T
Revenue (ttm)	41.61T
Net Income (ttm)	7.89T
Shares Out	n/a
EPS (ttm)	14,574.49
PE Ratio	28.58
Forward PE	14.20
Dividend	228.85 (1.59%)
Ex-Dividend Date	Aug 22, 2025

Volume	1,034
Average Volume	3,130
Open	14,730
Previous Close	14,540
Day's Range	14,560 - 15,020
52-Week Range	9,500 - 16,290
Beta	n/a
RSI	53.10
Earnings Date	Nov 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD